NASDAQ:SRPT - Sarepta Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $144.67
Forecasted Upside: 83.59 %
Number of Analysts: 23
Breakdown:
1 Sell Ratings
9 Hold Ratings
13 Buy Ratings
0 Strong Buy Ratings

^$78.80 As of 06/21/2021 06:23 PM ET

▼ -0.55 (-0.69%)

1 month | 3 months | 12 months

Get New Sarepta Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SRPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRPT

^$144.67

▲ +83.59% Upside Potential

This price target is based on 23 analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $144.67, with a high forecast of $221.00 and a low forecast of $73.00. The average price target represents a 83.59% upside from the last price of $78.80.

Current Consensus is Buy

The current consensus among 23 investment analysts is to buy stock in Sarepta Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
20 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
19 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
20 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
18 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
15 buy ratings
7 hold ratings
1 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
12 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
12 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
13 buy ratings
9 hold ratings
1 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
6/14/2021	BTIG Research	Initiated Coverage	Buy	$110.00	High
5/3/2021	Needham & Company LLC	Initiated Coverage	Buy	$166.00	High
4/19/2021	Morgan Stanley	Lower Price Target	Equal Weight	$95.00 ➝ $93.00	Low
4/16/2021	William Blair	Reiterated Rating	Buy		Low
3/21/2021	SVB Leerink	Reiterated Rating	Buy		Low
3/2/2021	Royal Bank of Canada	Lower Price Target	Outperform	$143.00 ➝ $132.00	High
3/2/2021	Needham & Company LLC	Reiterated Rating	Buy	$166.00	High
3/2/2021	SVB Leerink	Boost Price Target	Outperform	$125.00 ➝ $126.00	High
3/2/2021	Piper Sandler	Lower Price Target	Neutral	$140.00 ➝ $130.00	High
2/26/2021	Mizuho	Boost Price Target	Buy	$158.00 ➝ $160.00	High
1/12/2021	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		High
1/12/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Reiterated Rating	Buy ➝ Neutral	$215.00 ➝ $108.00	Medium
1/11/2021	UBS Group	Downgrade	Buy ➝ Neutral		High
1/8/2021	Oppenheimer	Reiterated Rating	Hold ➝ Neutral		High
1/8/2021	Credit Suisse Group	Lower Price Target	Neutral	$156.00 ➝ $73.00	N/A
1/8/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Underweight	$96.00	N/A
1/8/2021	Robert W. Baird	Lower Price Target	Outperform	$223.00 ➝ $110.00	N/A
1/8/2021	Cowen	Lower Price Target	Outperform	$213.00 ➝ $114.00	N/A
1/8/2021	Needham & Company LLC	Lower Price Target	Buy	$182.00 ➝ $166.00	N/A
1/8/2021	Barclays	Lower Price Target	Positive ➝ Overweight	$192.00 ➝ $125.00	N/A
1/8/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$217.00 ➝ $128.00	N/A
1/8/2021	Royal Bank of Canada	Lower Price Target	Outperform	$200.00 ➝ $143.00	N/A
1/8/2021	Mizuho	Lower Price Target	Buy	$204.00 ➝ $158.00	N/A
1/8/2021	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$182.00 ➝ $95.00	N/A
1/8/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A
1/8/2021	SVB Leerink	Lower Price Target	Outperform	$197.00 ➝ $125.00	N/A
1/4/2021	Piper Sandler	Boost Price Target	Overweight	$200.00 ➝ $240.00	N/A
12/14/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target		$190.00 ➝ $215.00	Low
12/14/2020	Smith Barney Citigroup	Boost Price Target		$190.00 ➝ $215.00	Low
12/14/2020	Credit Suisse Group	Lower Price Target	Neutral	$162.00 ➝ $156.00	Medium
12/8/2020	Mizuho	Boost Price Target	Buy	$192.00 ➝ $204.00	High
11/11/2020	Berenberg Bank	Initiated Coverage	Hold	$140.00	Medium
11/6/2020	Credit Suisse Group	Lower Price Target	Neutral	$167.00 ➝ $162.00	High
11/6/2020	SVB Leerink	Lower Price Target	Outperform	$214.00 ➝ $197.00	High
10/28/2020	UBS Group	Initiated Coverage	Buy	$212.00	Low
10/11/2020	Royal Bank of Canada	Reiterated Rating	Buy		Low
9/15/2020	Citigroup	Boost Price Target	Buy	$177.00 ➝ $190.00	Medium
8/31/2020	HC Wainwright	Lower Price Target	Buy	$260.00 ➝ $221.00	Low
8/24/2020	Raymond James	Initiated Coverage	Outperform	$200.00	High
8/21/2020	Bank of America	Lower Price Target	Buy	$190.00 ➝ $189.00	Medium
8/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$185.00 ➝ $167.00	High
8/10/2020	Morgan Stanley	Boost Price Target	Overweight	$172.00 ➝ $182.00	Low
8/4/2020	Piper Sandler	Lower Price Target	Overweight	$206.00 ➝ $200.00	Low
8/3/2020	Credit Suisse Group	Reiterated Rating	Buy		Low
6/22/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$160.00 ➝ $190.00	Low
6/16/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	Medium
6/10/2020	Bank of America	Reiterated Rating	Buy	$180.00	High
6/8/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
6/8/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/17/2020	Nomura	Reiterated Rating	Buy	$230.00	High
5/15/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		High
5/15/2020	Robert W. Baird	Reiterated Rating	Buy	$192.00	High
5/15/2020	HC Wainwright	Reiterated Rating	Buy	$260.00	High
5/7/2020	Needham & Company LLC	Initiated Coverage	Buy	$182.00	High
5/7/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	High
5/7/2020	Oppenheimer	Reiterated Rating	Hold		High
5/6/2020	Royal Bank of Canada	Reiterated Rating	Buy	$182.00	Low
4/30/2020	Mizuho	Reiterated Rating	Buy	$183.00	Low
4/15/2020	Morgan Stanley	Lower Price Target	Overweight	$173.00 ➝ $172.00	Low
3/30/2020	Mizuho	Initiated Coverage	Buy	$183.00	High
2/28/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$172.00 ➝ $160.00	High
2/27/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$211.00 ➝ $217.00	High
2/27/2020	JMP Securities	Lower Price Target	Outperform	$280.00 ➝ $217.00	High
2/25/2020	Nomura Securities	Reiterated Rating	Buy	$230.00	High
1/23/2020	SVB Leerink	Reiterated Rating	Buy	$216.00	Low
1/14/2020	Credit Suisse Group	Reiterated Rating	Buy	$185.00	Low
1/14/2020	Cowen	Reiterated Rating	Buy	$213.00	High
1/7/2020	Bank of America	Reiterated Rating	Buy	$187.00	High
12/30/2019	Oppenheimer	Reiterated Rating	Hold		Low
12/26/2019	Citigroup	Reiterated Rating	Buy	$177.00	Low
12/25/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/24/2019	The Goldman Sachs Group	Reiterated Rating	Buy	$180.00	Low
12/24/2019	Morgan Stanley	Boost Price Target	Overweight	$160.00 ➝ $173.00	Low
12/24/2019	Credit Suisse Group	Reiterated Rating	Overweight ➝ Outperform	$190.00 ➝ $185.00	Low
12/23/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$210.00	N/A
12/23/2019	Royal Bank of Canada	Lower Price Target	Outperform	$215.00 ➝ $200.00	Medium
12/20/2019	Robert W. Baird	Boost Price Target	Outperform	$181.00 ➝ $192.00	Low
12/18/2019	Nomura Securities	Reiterated Rating	Buy	$230.00	Low
12/17/2019	Citigroup	Boost Price Target	Buy	$167.00 ➝ $177.00	Low
12/15/2019	Cowen	Initiated Coverage	Buy	$213.00	Medium
12/15/2019	Barclays	Reiterated Rating	Buy	$202.00	Medium
12/13/2019	HC Wainwright	Boost Price Target		$160.00 ➝ $260.00	Low
12/13/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$175.00 ➝ $211.00	High
12/13/2019	SVB Leerink	Reiterated Rating	Outperform	$186.00 ➝ $216.00	Medium
12/13/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$185.00 ➝ $210.00	High
12/13/2019	Credit Suisse Group	Boost Price Target	Outperform	$185.00 ➝ $190.00	High
12/13/2019	Janney Montgomery Scott	Boost Price Target	Buy	$160.00 ➝ $175.00	High
12/13/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$215.00	High
11/18/2019	Citigroup	Lower Price Target	Buy ➝ Positive	$180.00 ➝ $167.00	Low
11/8/2019	Credit Suisse Group	Lower Price Target	Outperform	$201.00 ➝ $185.00	High
11/1/2019	Guggenheim	Initiated Coverage	Buy	$183.00	High
10/11/2019	Morgan Stanley	Lower Price Target	Overweight	$220.00 ➝ $160.00	Low
10/8/2019	Oppenheimer	Reiterated Rating	Hold		Low
9/27/2019	Piper Jaffray Companies	Set Price Target	Buy	$185.00	Low
9/27/2019	Citigroup	Lower Price Target	Buy	$185.00 ➝ $180.00	Medium
9/24/2019	Royal Bank of Canada	Set Price Target	Buy	$204.00	High
9/13/2019	HC Wainwright	Set Price Target	Buy	$160.00	Low
8/21/2019	Needham & Company LLC	Lower Price Target	Buy	$196.00 ➝ $170.00	Low
8/20/2019	Royal Bank of Canada	Lower Price Target	Outperform	$204.00	Low
8/20/2019	Cantor Fitzgerald	Lower Price Target	Overweight	$231.00 ➝ $175.00	Low
8/20/2019	Robert W. Baird	Lower Price Target	Outperform	$202.00 ➝ $181.00	High
8/20/2019	Bank of America	Lower Price Target	Buy	$200.00 ➝ $189.00	High
8/20/2019	Credit Suisse Group	Lower Price Target	Outperform	$207.00 ➝ $201.00	High
8/20/2019	Janney Montgomery Scott	Lower Price Target	Buy	$200.00 ➝ $175.00	High
8/20/2019	HC Wainwright	Reiterated Rating	Buy	$160.00 ➝ $267.00	High
8/20/2019	Piper Jaffray Companies	Lower Price Target	Overweight	$208.00 ➝ $185.00	High
8/9/2019	William Blair	Reiterated Rating	Buy		Low
8/8/2019	Evercore ISI	Reiterated Rating	Buy	$200.00	High
7/9/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$165.00 ➝ $220.00	Medium
7/1/2019	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$188.00 ➝ $220.00	Low
6/17/2019	HC Wainwright	Set Price Target	Buy	$267.00	Low
5/16/2019	Citigroup	Lower Price Target	Buy	$201.00 ➝ $190.00	Medium
5/14/2019	Morgan Stanley	Lower Price Target	Overweight	$169.00 ➝ $165.00	Medium
5/9/2019	Royal Bank of Canada	Lower Price Target	Outperform	$191.00 ➝ $188.00	High
4/17/2019	BTIG Research	Set Price Target	Buy	$190.00	High
4/11/2019	Evercore ISI	Initiated Coverage	Outperform	$175.00	High
3/31/2019	Cowen	Reiterated Rating	Buy	$213.00	Low
3/28/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$200.00 ➝ $208.00	Low
3/12/2019	BMO Capital Markets	Initiated Coverage	Outperform		Low
3/11/2019	Credit Suisse Group	Reiterated Rating	Outperform ➝ Outperform	$189.00 ➝ $207.00	Low
3/5/2019	SVB Leerink	Reiterated Rating	Outperform		Low
3/4/2019	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$161.00 ➝ $169.00	Low
3/1/2019	Citigroup	Boost Price Target	Buy ➝ Buy	$188.00 ➝ $201.00	Low
2/28/2019	Nomura Securities	Boost Price Target	Buy ➝ Buy	$205.00 ➝ $230.00	Low
2/28/2019	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$217.00 ➝ $231.00	High
2/27/2019	JMP Securities	Reiterated Rating	Buy	$270.00	High
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Buy		High
2/5/2019	BTIG Research	Set Price Target	Buy	$190.00	Low
1/30/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$168.00 ➝ $200.00	High
1/17/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$164.00	Low
1/8/2019	Janney Montgomery Scott	Set Price Target	Buy	$200.00	Medium
1/4/2019	HC Wainwright	Set Price Target	Buy	$267.00	High
12/28/2018	BTIG Research	Set Price Target	Buy	$190.00	Medium
12/10/2018	HC Wainwright	Set Price Target	Buy	$267.00	Low
11/26/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$217.00	High
11/6/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$174.00 ➝ $188.00	Medium
10/26/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$189.00 ➝ $168.00	Low
10/12/2018	Sanford C. Bernstein	Initiated Coverage	Outperform	$170.00	High
10/4/2018	Credit Suisse Group	Boost Price Target		$178.00 ➝ $189.00	High
10/4/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$189.00	High
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$217.00	High
9/26/2018	Royal Bank of Canada	Reiterated Rating	Outperform	$187.00 ➝ $200.00	Medium
9/24/2018	BTIG Research	Set Price Target	Buy	$190.00	Low
9/24/2018	Needham & Company LLC	Lower Price Target	Buy	$196.00	Low
9/21/2018	HC Wainwright	Reiterated Rating	Buy	$267.00	High
9/14/2018	Bank of America	Initiated Coverage	Buy ➝ Buy	$199.00	Low
9/6/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$178.00	Medium
9/4/2018	HC Wainwright	Set Price Target	Buy	$267.00	High
8/14/2018	Citigroup	Initiated Coverage	Buy		Medium
8/9/2018	Cowen	Reiterated Rating	Buy	$178.00	High
8/9/2018	HC Wainwright	Set Price Target	Buy	$267.00	High
8/1/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$163.00	Low
7/18/2018	HC Wainwright	Set Price Target	Buy	$267.00	Medium
6/25/2018	JMP Securities	Boost Price Target	Outperform	$275.00	Low
6/22/2018	SunTrust Banks	Boost Price Target	Buy	$176.00	High
6/21/2018	Nomura Securities	Boost Price Target	Buy ➝ Buy	$131.00 ➝ $205.00	Medium
6/21/2018	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$120.00 ➝ $202.00	Medium
6/20/2018	WBB Securities	Reiterated Rating	Buy		Low
6/20/2018	Royal Bank of Canada	Boost Price Target	Outperform	$189.00	Medium
6/20/2018	Needham & Company LLC	Boost Price Target	Buy	$109.00 ➝ $204.00	Medium
6/20/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$91.00 ➝ $163.00	High
6/20/2018	Cowen	Reiterated Rating	Outperform	$178.00	High
6/20/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform		High
6/20/2018	Barclays	Reiterated Rating	Overweight	$180.00	High
6/20/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$168.00	High
6/19/2018	William Blair	Reiterated Rating	Buy		High
6/19/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight		High
6/19/2018	HC Wainwright	Boost Price Target	Buy	$96.00 ➝ $267.00	High
6/15/2018	BTIG Research	Initiated Coverage	Buy	$120.00	High
6/11/2018	HC Wainwright	Reiterated Rating	Buy	$96.00	Low
5/18/2018	The Goldman Sachs Group	Boost Price Target	Buy	$84.00 ➝ $127.00	Low
5/15/2018	SVB Leerink	Boost Price Target	Hold ➝ Outperform	$88.00 ➝ $121.00	Low
5/11/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$55.00 ➝ $107.00	Low
5/7/2018	Needham & Company LLC	Boost Price Target	In-Line ➝ Buy	$75.00 ➝ $109.00	Low
5/4/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$87.00 ➝ $91.00	High
5/4/2018	Credit Suisse Group	Set Price Target	Outperform ➝ Buy	$100.00 ➝ $92.00	High
5/4/2018	Nomura Securities	Boost Price Target	Buy	$131.00	High
5/4/2018	Royal Bank of Canada	Boost Price Target	Outperform ➝ Positive	$98.00	High
5/4/2018	JMP Securities	Reiterated Rating	Outperform	$95.00 ➝ $90.00	High
5/4/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$90.00 ➝ $96.00	High
5/4/2018	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
5/4/2018	UBS Group	Downgrade	Outperform ➝ Market Perform		High
4/23/2018	HC Wainwright	Reiterated Rating	Buy	$92.00	High
4/5/2018	Credit Suisse Group	Set Price Target	Buy	$100.00	Medium
3/21/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$64.00 ➝ $87.00	Medium
3/16/2018	SunTrust Banks	Boost Price Target	Buy	$95.00	Medium
3/14/2018	Royal Bank of Canada	Reiterated Rating	Buy	$91.00	Medium
3/14/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$75.00 ➝ $95.00	Low
3/13/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$81.00 ➝ $100.00	Low
3/13/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$79.00 ➝ $92.00	Medium
3/12/2018	Credit Suisse Group	Reiterated Rating	Hold	$81.00	High
3/12/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$75.00 ➝ $92.00	High
3/12/2018	Piper Jaffray Companies	Reiterated Rating	Overweight	$83.00 ➝ $76.12	High
3/8/2018	SunTrust Banks	Boost Price Target	Buy	$76.00	Medium
3/6/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $64.00	Low
3/2/2018	Credit Suisse Group	Set Price Target	Buy	$81.00	Low
3/2/2018	Nomura Securities	Boost Price Target	Buy	$96.00	High
3/2/2018	HC Wainwright	Set Price Target	Buy	$75.00	High
3/2/2018	Piper Jaffray Companies	Reiterated Rating	Overweight		High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight ➝ Overweight	$63.00 ➝ $75.00	Low
2/12/2018	HC Wainwright	Set Price Target	Buy	$75.00	High
2/5/2018	William Blair	Reiterated Rating	Outperform		High
1/23/2018	Barclays	Reiterated Rating	Hold	$55.00	Low
1/22/2018	Royal Bank of Canada	Initiated Coverage	Outperform ➝ Outperform		High
1/19/2018	SVB Leerink	Reiterated Rating	Outperform	$77.00	Low
1/9/2018	HC Wainwright	Reiterated Rating	Buy	$75.00	Low
1/3/2018	Janney Montgomery Scott	Initiated Coverage	Buy ➝ Buy	$75.00	Medium
1/3/2018	HC Wainwright	Set Price Target	Buy	$75.00	Low
12/27/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	Low
12/27/2017	UBS Group	Reiterated Rating	Outperform	$76.00 ➝ $56.51	Low
12/1/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$75.00	High
10/27/2017	Needham & Company LLC	Reiterated Rating	Buy		N/A
10/26/2017	Barclays	Boost Price Target	Equal Weight	$46.00 ➝ $49.00	N/A
10/26/2017	Piper Jaffray Companies	Reiterated Rating	Overweight		N/A
10/17/2017	Robert W. Baird	Reiterated Rating	Buy	$101.00	N/A
10/16/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	N/A
10/6/2017	The Goldman Sachs Group	Reiterated Rating	Buy ➝ Buy	$71.00	N/A
10/3/2017	Royal Bank of Canada	Reiterated Rating	Buy	$64.00	Low
10/2/2017	William Blair	Reiterated Rating	Outperform		Low
10/2/2017	Nomura Instinet	Reiterated Rating	Buy	$84.00	Low
10/2/2017	Credit Suisse Group	Reiterated Rating	Outperform	$81.00	Low
10/2/2017	Robert W. Baird	Reiterated Rating	Outperform	$101.00	High
10/2/2017	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$60.00	High
9/30/2017	SVB Leerink	Reiterated Rating	Outperform	$66.00	High
9/25/2017	Oppenheimer	Reiterated Rating	Buy		Low
9/25/2017	JPMorgan Chase & Co.	Reiterated Rating	Hold		Low
9/15/2017	Royal Bank of Canada	Initiated Coverage	Positive		Low
9/14/2017	Cowen	Reiterated Rating	Outperform	$69.00	Medium
9/7/2017	SunTrust Banks	Reiterated Rating	Buy	$56.00	High
9/7/2017	William Blair	Reiterated Rating	Outperform		High
9/7/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00 ➝ $55.00	High
9/7/2017	Oppenheimer	Reiterated Rating	Buy	$76.00	Low
9/7/2017	Credit Suisse Group	Boost Price Target	Outperform	$5.65 ➝ $81.00	High
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$46.00	Medium
9/6/2017	Needham & Company LLC	Reiterated Rating	Buy	$75.00	Low
9/6/2017	Robert W. Baird	Reiterated Rating	Outperform	$101.00	Low
9/5/2017	Nomura Securities	Reiterated Rating	Buy	$84.00	Low
7/27/2017	William Blair	Reiterated Rating	Outperform		Low
7/24/2017	Janney Montgomery Scott	Boost Price Target	Buy ➝ Fair Value	$65.00 ➝ $73.00	High
7/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00 ➝ $96.00	Low
7/20/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$31.00 ➝ $33.00	High
7/20/2017	Royal Bank of Canada	Boost Price Target	Outperform ➝ Outperform	$60.00 ➝ $64.00	High
7/20/2017	Cowen	Reiterated Rating	Outperform	$62.00 ➝ $69.00	High
7/20/2017	SunTrust Banks	Reiterated Rating	Buy		High
7/20/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$50.00	High
7/18/2017	Credit Suisse Group	Set Price Target	Buy	$64.00	High
7/18/2017	SVB Leerink	Reiterated Rating	Buy	$52.00 ➝ $60.00	Low
7/12/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00	Low
7/3/2017	SVB Leerink	Reiterated Rating	Outperform		Medium
6/30/2017	Credit Suisse Group	Reiterated Rating	Outperform	$64.00	Low
6/30/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$31.00	Low
6/22/2017	Royal Bank of Canada	Reiterated Rating	Buy	$60.00	Medium
6/8/2017	Oppenheimer	Set Price Target	Buy	$76.00	Low
5/23/2017	Nomura Securities	Reiterated Rating	Buy	$84.00	Medium
5/18/2017	Piper Jaffray Companies	Set Price Target	Buy	$43.00	High
5/2/2017	SunTrust Banks	Reiterated Rating	Buy	$45.00	Low
5/2/2017	Oppenheimer	Reiterated Rating	Outperform	$76.00	Low
4/29/2017	SVB Leerink	Reiterated Rating	Outperform	$47.00 ➝ $52.00	Medium
4/28/2017	Cowen	Reiterated Rating	Buy		Low
4/28/2017	Credit Suisse Group	Reiterated Rating	Outperform	$64.00	Low
4/28/2017	Royal Bank of Canada	Lower Price Target	Outperform ➝ Outperform	$91.00 ➝ $60.00	High
4/23/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00	High
4/6/2017	Jefferies Financial Group	Reiterated Rating	Hold	$27.00	Medium
4/6/2017	SunTrust Banks	Boost Price Target		$30.00 ➝ $31.00	Low
4/5/2017	SunTrust Banks	Upgrade	Hold ➝ Buy	$30.00 ➝ $30.97	High
3/26/2017	Oppenheimer	Set Price Target	Buy	$76.00	High
3/11/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$42.00	High
3/11/2017	Cowen	Reiterated Rating	Outperform	$62.00	N/A
3/2/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$27.00 ➝ $47.00	N/A
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$84.00	N/A
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A
3/1/2017	Piper Jaffray Companies	Set Price Target	Buy	$43.00	N/A
3/1/2017	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$32.00 ➝ $27.00	N/A
3/1/2017	Jefferies Financial Group	Reiterated Rating	Hold	$27.00 ➝ $130.00	N/A
3/1/2017	Needham & Company LLC	Lower Price Target	Buy	$78.00 ➝ $75.00	N/A
3/1/2017	Royal Bank of Canada	Lower Price Target	Outperform	$98.00 ➝ $91.00	N/A
3/1/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
3/1/2017	JMP Securities	Lower Price Target		$48.00	N/A
3/1/2017	Royal Bank of Canada	Reiterated Rating	Outperform ➝ Outperform	$98.00 ➝ $91.00	N/A
2/28/2017	Oppenheimer	Set Price Target	Buy	$76.00	N/A
2/22/2017	Needham & Company LLC	Lower Price Target	Buy ➝ Buy	$81.00 ➝ $78.00	N/A
2/21/2017	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
2/21/2017	SVB Leerink	Reiterated Rating	Market Perform		N/A
2/16/2017	Oppenheimer	Reiterated Rating	Outperform	$76.00	N/A
2/1/2017	SVB Leerink	Reiterated Rating	Market Perform	$33.00 ➝ $32.00	N/A
1/12/2017	Cowen	Reiterated Rating	Outperform	$62.00	N/A
1/12/2017	Needham & Company LLC	Reiterated Rating	Positive	$81.00	N/A
1/11/2017	Jefferies Financial Group	Reiterated Rating	Hold		N/A
1/10/2017	Robert W. Baird	Reiterated Rating	Buy	$102.00	N/A
1/7/2017	Credit Suisse Group	Reiterated Rating	Outperform	$66.00	N/A
1/6/2017	JMP Securities	Lower Price Target	Outperform	$160.00 ➝ $65.00	N/A
1/4/2017	Morgan Stanley	Lower Price Target	Equal ➝ Equal Weight	$53.00 ➝ $33.00	N/A
1/3/2017	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$27.43 ➝ $65.00	N/A
12/23/2016	Oppenheimer	Reiterated Rating	Outperform	$76.00	N/A
12/23/2016	SVB Leerink	Reiterated Rating	Market Perform	$55.00 ➝ $33.00	N/A
12/22/2016	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$40.00	N/A
12/21/2016	Cowen	Reiterated Rating	Outperform	$62.00	N/A
12/20/2016	The Goldman Sachs Group	Initiated Coverage	Neutral	$40.00	N/A
12/16/2016	Royal Bank of Canada	Set Price Target	Buy	$106.00 ➝ $98.00	N/A
12/16/2016	Royal Bank of Canada	Boost Price Target	Outperform	$98.00 ➝ $106.00	N/A
12/14/2016	Jefferies Financial Group	Lower Price Target	Hold	$46.00 ➝ $32.00	N/A
12/4/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$106.00	N/A
11/30/2016	Credit Suisse Group	Reiterated Rating	Outperform	$41.00	N/A
11/29/2016	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
11/17/2016	JMP Securities	Reiterated Rating	Buy		N/A
11/14/2016	Credit Suisse Group	Set Price Target	Buy	$41.00	N/A
11/4/2016	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
11/2/2016	Oppenheimer	Reiterated Rating	Outperform	$76.00	N/A
10/28/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$108.00 ➝ $106.00	N/A
10/28/2016	Royal Bank of Canada	Lower Price Target	Outperform	$106.00	N/A
10/27/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A
10/27/2016	Wedbush	Reiterated Rating	Outperform	$72.00	N/A
10/27/2016	Morgan Stanley	Initiated Coverage	Equal ➝ Equal Weight	$53.00	N/A
10/26/2016	SVB Leerink	Reiterated Rating	Market Perform	$50.00 ➝ $55.00	N/A
10/18/2016	Credit Suisse Group	Initiated Coverage	Outperform	$68.00	N/A
10/17/2016	Oppenheimer	Reiterated Rating	Outperform	$76.00	N/A
10/17/2016	SunTrust Banks	Reiterated Rating	Hold	$52.00	N/A
10/17/2016	Royal Bank of Canada	Reiterated Rating	Outperform	$108.00	N/A
10/17/2016	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
10/10/2016	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
10/10/2016	Wedbush	Reiterated Rating	Outperform	$66.00 ➝ $72.00	N/A
10/8/2016	Needham & Company LLC	Reiterated Rating	Buy	$81.00	N/A
10/5/2016	Cowen	Reiterated Rating	Outperform	$64.00	N/A
10/4/2016	Piper Jaffray Companies	Set Price Target	Buy	$68.00	N/A
10/4/2016	Wedbush	Reiterated Rating	Outperform	$66.00 ➝ $66.00	N/A
10/2/2016	Jefferies Financial Group	Set Price Target	Hold	$50.00 ➝ $58.00	N/A
10/2/2016	William Blair	Reiterated Rating	Outperform	$88.00	N/A
10/2/2016	Oppenheimer	Reiterated Rating	Outperform	$76.00	N/A
9/30/2016	Robert W. Baird	Reiterated Rating	Outperform	$102.00	N/A
9/28/2016	JMP Securities	Boost Price Target	Outperform	$60.00 ➝ $90.00	N/A
9/20/2016	WBB Securities	Reiterated Rating	Strong-Buy	$40.00 ➝ $60.00	N/A
9/20/2016	Needham & Company LLC	Boost Price Target	Buy	$47.00 ➝ $81.00	N/A
9/20/2016	Wedbush	Reiterated Rating	Outperform	$66.00	N/A
9/20/2016	Cowen	Upgrade	Market Perform ➝ Outperform	$64.00	N/A
9/19/2016	Oppenheimer	Boost Price Target		$60.00 ➝ $76.00	N/A
9/19/2016	JMP Securities	Upgrade	Outperform	$10.00 ➝ $60.00	N/A
9/19/2016	Jefferies Financial Group	Upgrade	Underperform ➝ Hold	$50.00	N/A
9/19/2016	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$50.00	N/A
9/19/2016	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$83.00	N/A
9/19/2016	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight		N/A
9/19/2016	William Blair	Upgrade	Market Perform ➝ Outperform	$88.00	N/A
9/19/2016	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$30.00 ➝ $65.00	N/A
9/15/2016	JMP Securities	Reiterated Rating	Underperform	$10.00	N/A
9/15/2016	Jefferies Financial Group	Reiterated Rating	Underperform	$7.00	N/A
9/14/2016	SunTrust Banks	Upgrade	Reduce ➝ Neutral		N/A
9/14/2016	Oppenheimer	Reiterated Rating	Outperform	$60.00 ➝ $60.00	N/A
9/14/2016	Needham & Company LLC	Boost Price Target	Buy	$47.00 ➝ $81.00	N/A
8/15/2016	Cowen	Reiterated Rating	Market Perform		N/A
8/11/2016	Janney Montgomery Scott	Reiterated Rating	Neutral	$30.00	N/A
8/4/2016	SVB Leerink	Reiterated Rating	Underperform	$5.00	N/A
8/3/2016	Janney Montgomery Scott	Set Price Target	Hold	$30.00	N/A
7/26/2016	Oppenheimer	Reiterated Rating	Outperform	$60.00	N/A
7/24/2016	JMP Securities	Reiterated Rating	Underperform	$10.00	N/A
7/22/2016	Needham & Company LLC	Boost Price Target	Buy	$20.00 ➝ $26.00	N/A
7/19/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A
7/19/2016	Cowen	Reiterated Rating	Market Perform		N/A
7/18/2016	Robert W. Baird	Reiterated Rating	Outperform	$23.00	N/A
7/17/2016	Oppenheimer	Reiterated Rating	Buy	$60.00	N/A
6/27/2016	Robert W. Baird	Reiterated Rating	Outperform	$23.00	N/A
6/27/2016	William Blair	Reiterated Rating	Market Perform		N/A
6/25/2016	Jefferies Financial Group	Reiterated Rating	Underperform	$7.00	N/A
6/22/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A
6/21/2016	Oppenheimer	Reiterated Rating	Outperform	$60.00	N/A

(Data available from 6/21/2016 forward)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $78.80

$77.38

$79.69

50 Day Range

MA: $75.56

$69.38

$86.75

52 Week Range

Now: $78.80

$67.68

$181.83

Volume

1,019,792 shs

Average Volume

1,702,595 shs

Market Capitalization

$6.29 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Sarepta Therapeutics?

The following sell-side analysts have issued stock ratings on Sarepta Therapeutics in the last year: Bank of America Co., Barclays PLC, Berenberg Bank, BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, HC Wainwright, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, UBS Group AG, and William Blair.
View the latest analyst ratings for SRPT.

What is the current price target for Sarepta Therapeutics?

21 Wall Street analysts have set twelve-month price targets for Sarepta Therapeutics in the last year. Their average twelve-month price target is $144.67, suggesting a possible upside of 82.3%. HC Wainwright has the highest price target set, predicting SRPT will reach $221.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $73.00 for Sarepta Therapeutics in the next year.
View the latest price targets for SRPT.

What is the current consensus analyst rating for Sarepta Therapeutics?

Sarepta Therapeutics currently has 1 sell rating, 9 hold ratings and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRPT will outperform the market and that investors should add to their positions of Sarepta Therapeutics.
View the latest ratings for SRPT.

What other companies compete with Sarepta Therapeutics?

Other companies that are similar to Sarepta Therapeutics include MERCK Kommanditgesellschaft auf Aktien, Horizon Therapeutics Public, Alnylam Pharmaceuticals, Catalent, UCB, Viatris, Elanco Animal Health, BioMarin Pharmaceutical, Zai Lab, Grifols, Dr. Reddy's Laboratories, CureVac, Maravai LifeSciences, Ono Pharmaceutical and Teva Pharmaceutical Industries.

How do I contact Sarepta Therapeutics' investor relations team?

Sarepta Therapeutics' physical mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company's listed phone number is 617-274-4000 and its investor relations email address is [email protected] The official website for Sarepta Therapeutics is www.sareptatherapeutics.com.